MPL- OXYCODONE/NALOXONE oxycodone hydrochloride / naloxone hydrochloride 2.5/1.25mg modified release tablet blister pack Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mpl- oxycodone/naloxone oxycodone hydrochloride / naloxone hydrochloride 2.5/1.25mg modified release tablet blister pack

mundipharma pty ltd - oxycodone hydrochloride, quantity: 2.5 mg; naloxone hydrochloride dihydrate, quantity: 1.37 mg (equivalent: naloxone hydrochloride?, qty 1.25 mg) - tablet, modified release - excipient ingredients: hyprolose; ethylcellulose; stearyl alcohol; lactose monohydrate; purified talc; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - mpl-oxycodone/naloxone modified release tablets are indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and ,- requires daily, continuous, long term treatment.,mpl-oxycodone/naloxone modified release tablets are not indicated for use in chronic noncancer pain other than in exceptional circumstances.,mpl-oxycodone/naloxone modified release tablets are not indicated as an as-needed (prn) analgesia.,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,mpl-oxycodone/naloxone is indicated as second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Epethinan 5 mg/2.5 mg prolonged release tablet Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

epethinan 5 mg/2.5 mg prolonged release tablet

acino ag - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 5 / 2.5 milligram(s) - natural opium alkaloids; oxycodone, combinations

Epethinan 10 mg/5 mg prolonged release tablet Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

epethinan 10 mg/5 mg prolonged release tablet

acino ag - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 10 / 5 milligram(s) - natural opium alkaloids; oxycodone, combinations

Epethinan 20 mg/10 mg prolonged release tablet Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

epethinan 20 mg/10 mg prolonged release tablet

acino ag - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 20 / 10 milligram(s) - natural opium alkaloids; oxycodone, combinations

Epethinan 40 mg/20 mg prolonged release tablet Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

epethinan 40 mg/20 mg prolonged release tablet

acino ag - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 40 / 20 milligram(s) - natural opium alkaloids; oxycodone, combinations

Oxycodone Juno oxycodone hydrochloride 50 mg / 1 mL solution for infusion ampoule Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 50 mg / 1 ml solution for infusion ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 200 mg / 20 mL solution for injection ampoule Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 200 mg / 20 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 20 mg / 2 mL solution for injection ampoule Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 20 mg / 2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 10 mg / 1 mL solution for injection ampoule Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 10 mg / 1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

JUNALOX naloxone hydrochloride (as dihydrate) 400 micrograms/1 mL solution for injection, ampoule Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

junalox naloxone hydrochloride (as dihydrate) 400 micrograms/1 ml solution for injection, ampoule

juno pharmaceuticals pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram/ml (equivalent: naloxone hydrochloride?, qty 400 microgram/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid - junalox is indicated for the treatment of opioid overdose.